• Review of strategic options draws strong interest in Australian business
• Linda Jenkinson steps down as Chair, Kate Hill appointed as Interim Chair
• Revenue of $93-99m expected in FY25, 15% growth and margin expansion in FY26
• $12 million in OPEX savings expected between FY24-FY26

MedAdvisor Limited (ASX: MDR) has announced an update on its strategic review, board changes, and financial guidance for FY25 and FY26. The company has also completed a $5 million placement to institutional and sophisticated investors and launched a $2 million share purchase plan. The strategic review has drawn strong interest in the company's Australian business, with several conditional, non-binding proposals received. The board has decided to evaluate all options to maximize shareholder value. Linda Jenkinson has stepped down as Chair, with Kate Hill appointed as Interim Chair. MedAdvisor has provided financial guidance, expecting revenue of $93-99 million in FY25 and targeting 15% revenue growth and margin expansion in FY26. The company has also announced an accelerated cost-out program, expected to deliver $12 million in OPEX savings between FY24-FY26. The equity raising will fund the execution of strategic and cost-optimization initiatives.

Revenue of $93-99 million expected in FY25, with revenue growth of approximately 15% and margin expansion expected from FY25 to FY26.

MedAdvisor is well positioned for a recovery in FY26, with key initiatives underway including an enhanced US sales structure, the launch of a next-generation patient engagement platform, and ongoing business optimisation and cost reductions.